The resistance to treatments from Raf and MEK inhibitors has led to clinical trials for combined therapy such treatment with dabrafenib and trametinib for un-resectable or metastatic melanoma with a B-RafV600E or B-RafV600K mutations. The gene discussed is MAP2K7; the disease is metastatic melanoma.